论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liu M, Hu G, Wang Y, Guo J, Liu L, Han X, Wang Z
Received 21 August 2017
Accepted for publication 1 December 2017
Published 17 January 2018 Volume 2018:11 Pages 375—381
DOI https://doi.org/10.2147/OTT.S149624
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Faris Farassati
Background: Our study retrospectively assesses the safety and efficacy of the
FOLFOX (oxaliplatin, fluorouracil, and leucovorin) versus DOF (docetaxel,
oxaliplatin, and fluorouracil) regimens in untreated locally advanced gastric
cancer (AGC).
Patients and
methods: A total of 108 patients underwent
DOF (N=58) and FOLFOX (N=50) regimens. The end points were overall response
rate (ORR), survival, and toxicity. Kaplan–Meier curve was used to estimate
overall survival (OS) and progression-free survival (PFS) and Cox regression
for multivariate analysis.
Results: The ORRs were 50% for DOF and 30% for FOLFOX groups (P <0.05), and disease control
rates were 91.4% and 72%, respectively. The median PFS and OS in DOF group were
significantly better than FOLFOX group (8.2 versus 6.4 months, P <0.05; 16.3 versus
11.2 months, P <0.001). Both
groups showed acceptable toxicity; all grades and grade 3–4 toxicity had no
significant differences (P =0.071; P =0.247). However, the incidence
of grade 3–4 peripheral neuropathy was significantly higher in DOF group
(10.3% versus 2%, P <0.05). In the
subgroup analysis for elderly AGC patients (≥65 years), administration of DOF
also resulted in a superior PFS (8.5 versus 5.9 months; P =0.038) and OS (15.3 versus 9.8
months; P =0.004) compared with FOLFOX.
However, DOF regimen was associated with more neutropenia (67% versus
30%; P <0.05), thrombocytopenia (61%
versus 52%; P <0.05), and peripheral
neuropathy (49% versus 22%; P <0.05).
Conclusion: DOF regimen was more effective than FOLFOX for AGC, both in younger and
older patients. The adverse effects of the two regimens were manageable. The
combination of docetaxel/oxaliplatin/fluorouracil was active and well tolerated
in AGC patients and deserves further evaluation. However, for elderly patients
with AGC, the DOF regimen was associated with worse toxicities; therefore, the
FOLFOX regimen might be a more suitable option.
Keywords: East Asian AGC patients, chemotherapy, safety, efficacy